Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 15831477
Vadlamudi RK, et al. (2005) p21-activated kinase 1 regulates microtubule dynamics by phosphorylating tubulin cofactor B. Mol Cell Biol 25, 3726-36 15831477
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S65-p - TBCB (human)
Modsite: GVDDKFYskLDQEDA SwissProt Entrez-Gene
Orthologous residues
TBCB (human): S65‑p, TBCB (mouse): S65‑p, TBCB (rat): S65‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  IMR-90 (fibroblast), MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE PAK1 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PAK1 (human) transfection of constitutively active enzyme, siRNA inhibition of enzyme, activation of upstream enzyme, pharmacological activator of upstream enzyme, co-immunoprecipitation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
siRNA EGF inhibit treatment-induced increase Pak1 siRNA

S128-p - TBCB (human)
Modsite: VRsFLKRsKLGRyNE SwissProt Entrez-Gene
Orthologous residues
TBCB (human): S128‑p, TBCB (mouse): S128‑p, TBCB (rat): S128‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site
Disease tissue studied:  breast cancer
Relevant cell lines - cell types - tissues:  IMR-90 (fibroblast), MCF-7 (breast cell)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE PAK1 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PAK1 (human) transfection of constitutively active enzyme, siRNA inhibition of enzyme, activation of upstream enzyme, pharmacological activator of upstream enzyme, co-immunoprecipitation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
siRNA EGF inhibit treatment-induced increase Pak1 siRNA